ad image

Phase II

1 / 1
Unlocking the Potential of Psychedelics for Postpartum Depression
Psychedelics

Unlocking the Potential of Psychedelics for Postpartum Depression

Greg Mayes, J.D.

Reunion Neuroscience

PAO-03-25-CL-05Mar 31, 2025
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
Proof-of-Concept Trial

Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH

PR-M11-20-014Nov 18, 2020
Haima Therapeutics
Clinical Trials

Haima Therapeutics Receives Phase II TVSF Award from the State of Ohio to Develop its SynthoPlate Product for Veterinary Use

Haima Therapeutics

PR-M07-20-NI-014Jul 10, 2020
VistaGen Therapeutics
Clinical Results

VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder

VistaGen Therapeutics

PR-M11-19-NI-019Nov 19, 2019
Sanifit Announces the Phase 2b CaLIPSO Trial of SNF472 Met  Endpoint in Slowing the Cardiovascular Calcification in Patients on Hemodialysis
Endpoints

Sanifit Announces the Phase 2b CaLIPSO Trial of SNF472 Met  Endpoint in Slowing the Cardiovascular Calcification in Patients on Hemodialysis

Nice Insight

PR-M10-19-NI-051Nov 01, 2019
Amgen
Positive Results

Amgen Announces Positive Results From Two Phase 3 BLINCYTO® Studies In Pediatric Patients

Amgen

PR-M09-19-NI-056Sep 27, 2019
Hovione
Phase II

Hovione Announces Successful End-of-Phase 2 Meeting with the FDA and Outlines Phase 3 Program for Minocycline Topical Gel

Hovione

PR-M09-19-NI-047Sep 20, 2019
SELLAS Life Sciences Group
Clinical Trials

SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial

SELLAS Life Sciences Group

PR-M04-18-NI-020-4444Apr 05, 2018
MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis
Clinical Trials

MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis

MediciNova

PR-M04-18-NI-014Apr 04, 2018
AbbVie
Clinical Trials

AbbVie Announces New Phase 2 Data for Upadacitinib Showing Clinical and Endoscopic Outcomes in Crohn's Disease at 52 Weeks

AbbVie

PR-M02-18-NI-83Feb 22, 2018
BerGenBio ASA
Clinical Trials

BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC

BerGenBio ASA

PR-M01-18-NI-035Jan 12, 2018
Regenerating Knee Cartilage with Stem Cells
Innovation

Regenerating Knee Cartilage with Stem Cells

Nigel Walker

Nice Insight

PAO-M07-17-NI-020Jul 18, 2017
1 / 1